Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau129pxo

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 4	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 5	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 6	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 7	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS 9	JUL 27	CA/CAplus enhanced with new citing references
NEWS 10	JUL 16	GBFULL adds patent backfile data to 1855
NEWS 11	JUL 21	USGENE adds bibliographic and sequence information
NEWS 12	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS 13	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data
NEWS 14	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS 15	AUG 17	CAS REGISTRY, the Global Standard for Chemical Research, Approaches 50 Millionth Registration Milestone
NEWS 16	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS 17	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS 18	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 21:11:07 ON 06 SEP 2009

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 21:11:14 ON 06 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2
DICTIONARY FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s ibandronic
L1 1 IBANDRONIC

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 114084-78-5 REGISTRY
ED Entered STN: 23 Apr 1988
CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-
(CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis- (9CI)
OTHER NAMES:
CN BPH 24
CN Ibandronate
CN Ibandronic acid
CN [1-Hydroxy-3-(methylpentylamino)propylidene]diphosphonic acid
MF C9 H23 N O7 P2
CI COM
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
      CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE,
      IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
      PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2,
      USPATFULL
        (*File contains numerically searchable property data)
    Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

             723 REFERENCES IN FILE CA (1907 TO DATE)
              29 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             726 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s ibandronic sodium
             1 IBANDRONIC
        344247 SODIUM
L2           0 IBANDRONIC SODIUM
                 (IBANDRONIC(W)SODIUM)

=> s 138844-81-2
L3           1 138844-81-2
                 (138844-81-2/RN)

=> s 138926-19-9
L4           1 138926-19-9
                 (138926-19-9/RN)

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   138844-81-2  REGISTRY
ED   Entered STN:  07 Feb 1992
CN   Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-,
     sodium salt (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-,
     monosodium salt (9CI)
OTHER NAMES:
CN   BM 21.0955
CN   BM 21.0955Na
CN   Bondronat
CN   Bondronate
CN   Boniva
CN   Bonviva
CN   Ibandronate sodium
MF   C9 H23 N O7 P2 . Na
CI   COM
```

SR   CA
LC   STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CASREACT, CHEMCATS, CIN, DDFU, DRUGU, EMBASE, IMSCOSEARCH,
       IMSPATENTS, IMSRESEARCH, MRCK*, PROMT, PROUSDDR, PS, SYNTHLINE,
       TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN (114084-78-5)



Na

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

              87 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
              87 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 2
      1 ANSWERS ARE AVAILABLE. SPECIFIED ANSWER NUMBER EXCEEDS ANSWER SET SIZE
The answer numbers requested are not in the answer set.
ENTER ANSWER NUMBER OR RANGE (1):end

=> d l4 1

L4   ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN   138926-19-9 REGISTRY
ED   Entered STN: 14 Feb 1992
CN   Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-,
     sodium salt, hydrate (1:1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phosphonic acid, [1-hydroxy-3-(methylpentylamino)propylidene]bis-,
     monosodium salt, monohydrate (9CI)
OTHER NAMES:
CN   BM 21.0955Na.H2O
CN   Ibandronate sodium monohydrate
CN   Monosodium ibandronate monohydrate
MF   C9 H23 N O7 P2 . H2 O . Na
SR   CAS Client Services
LC   STN Files: ADISINSIGHT, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS,
       CSCHEM, EMBASE, IMSPATENTS, IMSRESEARCH, MRCK*, PATDPASPC, PROUSDDR, PS,
       SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
CRN (114084-78-5)



25 REFERENCES IN FILE CA (1907 TO DATE)
25 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION
FULL ESTIMATED COST | 24.60 | 24.82

FILE 'CAPLUS' ENTERED AT 21:14:12 ON 06 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 4 Sep 2009 (20090904/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

=> s l3 or l4
87 L3
25 L4
L5 106 L3 OR L4

=> s amorphous
L6 301133 AMORPHOUS

=> s l5 and l6
L7 5 L5 AND L6

=> d l7 fbib ab hitstr 1-5

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2009:876533 CAPLUS
DN 151:181953
TI Solid and crystalline ibandronate sodium and processes for preparation thereof
IN Lifshitz-Liron, Revital; Bayer, Thomas; Aronhime, Judith; Pinchasov, Michael
PA Teva Pharmaceutical Industries Ltd., Israel
SO U.S., 32pp., Cont. of U.S. Ser. No. 410,825. now abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 7563918	B2	20090721	US 2006-644568		20061222
US 20070179119	A1	20070802			
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			US 2005-211062	B1	20050823
			US 2006-410825	B1	20060424
DE 202005021414	U1	20080424	DE 2005-202005021414		20050823
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			EP 2005-791142	A	20050823
EP 1930011	A2	20080611	EP 2008-2626		20050823
EP 1930011	A3	20080618			
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			EP 2005-791142	A3	20050823

PATENT FAMILY INFORMATION:
FAN 2006:333490

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006024024	A2	20060302	WO 2005-US30500	20050823
WO 2006024024	A3	20060629		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
CA 2576659	A1	20060302	CA 2005-2576659		20050823
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823
EP 1713489	A2	20061025	EP 2005-791142		20050823

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823
JP 2007512237	T	20070517	JP 2006-536948		20050823
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823
CN 101022812	A	20070822	CN 2005-80028503		20050823
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823
DE 202005021414	U1	20080424	DE 2005-202005021414		20050823
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			EP 2005-791142	A	20050823
EP 1930011	A2	20080611	EP 2008-2626		20050823
EP 1930011	A3	20080618			

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			EP 2005-791142	A3	20050823
IN 2007DN00555	A	20070817	IN 2007-DN555		20070122
			US 2004-604026P	P	20040823
			WO 2005-US30500	W	20050823
MX 2007002286	A	20080828	MX 2007-2286		20070222
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823
KR 2007043043	A	20070424	KR 2007-705922		20070314
			US 2004-604026P	P	20040823
			US 2005-690867P	P	20050616
			WO 2005-US30500	W	20050823

AB The present invention relates to solid amorphous and crystalline forms of ibandronate sodium. Thus, a solution of NaOH (0.63 g) in water/isopropanol (IPA) was added dropwise to a solution of amorphous ibandronic acid (5 g) in water/IPA at reflux temperature, and the reaction mixture

maintained at reflux temperature for 4 h to obtain a pH of 3.93-4.01. The reaction mixture was then cooled to room temperature, stirred for 72 h, and further cooled using an ice-bath. The precipitate was filtered, washed, and dried in a vacuum oven at 50° to give 4.4 g of ibandronate sodium crystal form F.

IT 138844-81-2P, Ibandronate sodium
RL: PEP (Physical, engineering or chemical process); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of solid amorphous and crystalline ibandronate sodium)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



Na

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:724495 CAPLUS
DN 147:125584
TI Novel polymorphic forms of ibandronate for tablets
IN Reddy, Muddasani Pulla; Usharani, Vattikuti; Chowdary, Nannapaneni Venkalah
PA Natco Pharma Limited, India
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007074475	A2	20070705	WO 2006-IN501	20061221
	WO 2007074475	A3	20070907		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

IN 2005-CH1936 A 20051227
IN 2005CH01936 A 20070720 IN 2005-CH1936 20051227

AB The present invention relates to novel and stable polymorphic forms of ibandronate monosodium monohydrate and processes for their preparation and pharmaceutical compns. containing them, such as tablets. Ibandronate monosodium monohydrate is useful as bone resorption inhibitor. The novel crystalline forms are designated as Form I, Form II and the amorphous ibandronate monosodium monohydrate as Form III. Thus, the reaction of 100 g of 3-(N-methyl-N-pentylamino)propionic acid-HCl and 49 g of crystalline phosphorous acid at 75°, followed by the addition of phosphorous trichloride and adjusting the pH to 4.3-4.4 using NaOH yielded 145 g of ibandronate. Ibandronate prepared (25 g) was dissolved in 200 mL of water, water was distilled of from the reaction mass and 100 mL of fresh water was added. The reaction mass was treated with 2 g of carbon and filtered. To the filtrate 200 mL of acetone were added at 50-60° resulting in immediate crystallization of ibandronate. The reaction mass was cooled to 25° and maintained for 1 h before filtration. The wet solid was washed with acetone and dried at 60° to get 20 g of Form I crystals of ibandronate monosodium monohydrate. Form I crystals of ibandronate monosodium monohydrate prepared were formulated into tablets containing equivalent to 150 mg of ibandronic acid per single dosage unit.

IT 138926-19-9P, Ibandronate sodium monohydrate
RL: PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(preparation of polymorphic forms of ibandronate monosodium monohydrate for tablets)

RN 138926-19-9 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt, hydrate (1:1:1) (CA INDEX NAME)



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:333490 CAPLUS
DN 144:338225
TI Preparation of solid and crystalline ibandronate sodium
IN Lifshitz-Liron, Revital; Bayer, Thomas; Aronhime, Judith
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceutical Usa, Inc.
SO PCT Int. Appl., 67 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2006024024	A2	20060302	WO 2005-US30500		20050823
	WO 2006024024	A3	20060629			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
	CA 2576659	A1	20060302	CA 2005-2576659		20050823
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				WO 2005-US30500	W	20050823
	EP 1713489	A2	20061025	EP 2005-791142		20050823
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU					
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				WO 2005-US30500	W	20050823
	JP 2007512237	T	20070517	JP 2006-536948		20050823
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				WO 2005-US30500	W	20050823
	CN 101022812	A	20070822	CN 2005-80028503		20050823
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				WO 2005-US30500	W	20050823
	DE 202005021414	U1	20080424	DE 2005-202005021414		20050823
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				EP 2005-791142	A	20050823
	EP 1930011	A2	20080611	EP 2008-2626		20050823
	EP 1930011	A3	20080618			
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616
				EP 2005-791142	A3	20050823
	IN 2007DN00555	A	20070817	IN 2007-DN555		20070122
				US 2004-604026P	P	20040823
				WO 2005-US30500	W	20050823
	MX 2007002286	A	20080828	MX 2007-2286		20070222
				US 2004-604026P	P	20040823
				US 2005-690867P	P	20050616

				WO 2005-US30500	W 20050823
	KR 2007043043	A	20070424	KR 2007-705922	20070314
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				WO 2005-US30500	W 20050823

PATENT FAMILY INFORMATION:

FAN 2009:876533

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 7563918	B2	20090721	US 2006-644568	20061222
	US 20070179119	A1	20070802		
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				US 2005-211062	B1 20050823
				US 2006-410825	B1 20060424
	DE 202005021414	U1	20080424	DE 2005-202005021414	20050823
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				EP 2005-791142	A 20050823
	EP 1930011	A2	20080611	EP 2008-2626	20050823
	EP 1930011	A3	20080618		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
				US 2004-604026P	P 20040823
				US 2005-690867P	P 20050616
				EP 2005-791142	A3 20050823

AB The present invention relates to solid amorphous and crystalline forms of ibandronate sodium. Thus, ibandronate sodium was dissolved in DMSO and 1-butanol was added to it, and the precipitate was isolated by vacuum filtration, washed with 1-butanol and dried at 50° to obtain ibandronate sodium crystal form C.

IT 138844-81-2P
RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of solid amorphous and crystalline forms of ibandronate sodium)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:11476 CAPLUS

DN 144:94242
TI Solid and crystalline ibandronic acid
IN Bayer, Thomas; Dolitzky, Ben-Zion; Lifshitz-Liron, Revital; Perutski, Inna; Pinchasov, Michael
PA Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceutical USA, Inc.
SO PCT Int. Appl., 67 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006002348	A2	20060105	WO 2005-US22410	20050623
	WO 2006002348	A3	20060504		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
	CA 2571433	A1	20060105	CA 2005-2571433	20050623
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				WO 2005-US22410	W 20050623
	EP 1687007	A2	20060809	EP 2005-763415	20050623
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				WO 2005-US22410	W 20050623
	US 20070161606	A1	20070712	US 2006-525804	20060922
	US 7511174	B2	20090331		
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				US 2005-165481	B1 20050622
				US 2006-331995	B1 20060112
	IN 2006DN07758	A	20070817	IN 2006-DN7758	20061220
				US 2004-582500P	P 20040623
				WO 2005-US22410	W 20050623
	MX 2007000087	A	20071106	MX 2007-87	20061220
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				WO 2005-US22410	W 20050623
	US 20090023949	A1	20090122	US 2008-218197	20080710

				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				US 2005-165481	B1 20050622
				US 2006-331995	B1 20060112
				US 2006-525804	A3 20060922
US	20090069598	A1	20090312	US 2008-288025	20081015
				US 2004-582500P	P 20040623
				US 2004-620016P	P 20041018
				US 2005-690868P	P 20050616
				US 2005-165481	B1 20050622
				US 2006-331995	B1 20060112
				US 2006-525804	A3 20060922

AB Provided are novel crystalline and amorphous forms of ibandronic acid, methods for their preparation, and pharmaceutical compns. containing them.

Also provided are methods for purifying and assaying ibandronic acid in any crystalline form (or amorphous). Amorphous ibandronic acid was prepared by drying a solution and a crystal form S1 prepared from the amorphous form by adding acetone to a solution

IT 138844-81-2P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(solid and crystalline ibandronic acid)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



Na

OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:612312 CAPLUS

DN 143:97528

TI An improved process for the preparation of alkyl- and aryl-substituted α-hydroxy-1,1-ethanediphosphonic acids and salts thereof by solvent-free reaction of carboxylic acids with phosphorous acid and phosphorus oxychloride

IN Grassi, Simona; Volante, Anna

PA Lyogen Limited, Cyprus

SO PCT Int. Appl., 9 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2005063779	A2	20050714	WO 2004-EP14556		20041222
	WO 2005063779	A3	20050929			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				IT 2003-MI2582	A	20031223
				IT 2004-MI80	A	20040122
	IT 2004MI0080	A1	20040422	IT 2004-MI80		20040122
	CA 2551230	A1	20050714	CA 2004-2551230		20041222
				IT 2003-MI2582	A	20031223
				IT 2004-MI80	A	20040122
				WO 2004-EP14556	W	20041222
	EP 1716161	A2	20061102	EP 2004-804152		20041222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
				IT 2003-MI2582	A	20031223
				IT 2004-MI80	A	20040122
				WO 2004-EP14556	W	20041222
	US 20070112197	A1	20070517	US 2006-584022		20061025
				IT 2003-MI2582	A	20031223
				IT 2004-MI80	A	20040122
				WO 2004-EP14556	W	20041222

OS CASREACT 143:97528; MARPAT 143:97528

AB α-Hydroxy-1,1-ethanediphosphonic acids R(CH2)mC(OH)[PO(OH)2]2 [m = 1-8; R = dialkylamino or 5- or 6-membered (hetero)aryl, preferably imidazolyl and pyridinyl], preferably risedronic, zoledronic and ibandronic acids, useful in therapy as inhibitors of bone reabsorption (no data) were prepared by reaction carboxylic acids R(CH2)mCOOH (same m, R) with 2-4 equiv of POCl3 and 8-12 equiv of H3PO3, preferably the carboxylic acid:POCl3:H3PO3 ratio is 1:3:10. In an example, addition of 0.19 mol of POCl3 to a mixture of 0.06 mol of (3-pyridinyl)acetic acid and 0.58 mol of H3PO3 followed by stirring at 60-70° for 24 h with subsequent aqueous work-up gave 1-hydroxy-2-(3-pyridinyl)-1,1-ethanediphosphonic acid (risedronic acid) in 60% yield. Amorphous monosodium salt of 1-hydroxy-2-[(methyl)(pentyl)amino]-1,1-1,1-ethanediphosphonic acid (monosodium ibandronate), useful in the pharmaceutical use due of its increased bioavailability (no data) was prepared by neutralization of 10 g of analogously prepared ibandronic acid in 200 mL of water by 1M NaOH to pH 4.3-4.4 and lyophilization of the resulting solution

IT 138844-81-2DP, amorphous
RL: SPN (Synthetic preparation); PREP (Preparation)
(improved process for preparation of α-hydroxy-1,1-ethanediphosphonic acids by solvent-free phosphonation of carboxylic acids by phosphorous acid and phosphorus oxychloride)

RN 138844-81-2 CAPLUS

CN Phosphonic acid, P,P'-[1-hydroxy-3-(methylpentylamino)propylidene]bis-, sodium salt (1:1) (CA INDEX NAME)



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT